Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CVM Example of a stock that busts out of cup without even bothering to form a handle .. this could be ADVC.
ADVC Weekly .. Volume .. Wow.
Company is still growing ... MACD just starting to turn up ... a little consolidation is to be expected (but not required with a move like this, lol)
looks to me like ADVC will continue to run.... wouldn't be surprised to see a little more dipping tomorrow though... like a hammer doji before the next leg. Very unlikely that this thing stops this powerful move after only five days from breakout. Golden cross has yet to happen .. but it wants too, bad. This stock is undervalued ... end of story.
Agreed. I think CNES is still strong.
CNES Forming Handle
A little nerve racking for CNES holders today (myself included) .. but the trend is still up, and strong. Good support at .0012. CMF still intact, as are the averages, and other indicators. Also, the 50% rule says hold. (you may want to look that one up)
On CYOS .. I've been telling people to look out for this thing for more than a week- then yesterday I got bored with it and took it off my list. What are the odds? Nice little rally today for them.
Very happy with LFWK right now .. this looks like a strong run building here .. next resistance .018!
WTVN Breaking Out Of Handle
LFWK @ .011 ... guess I'm having a party. It would be more fun if CNES wasn't down so much .. but whatever ... I added a lot today at this level.
PMED Moving
Gotta go to work for a bit .. if LFWK breaks .01 .. there's gonna be a party at my house. My NEW house! LOL!!
GWGO Sweet! Just made it in under the wire.
LFWK It is our time.
JKRI I got a hunch that this is a stock to hold for a while.
GWGO gonna blow here
Not much time left .. grab these 5's and 6's while you can imo. I sure did.
now why don't I buy those beauties that I go around posting .. missed it this morning. Dang!
lol .. solid break from consolidation .. I like it.
Congrats on LTII bagheera .. good catch!
ONEV on launchpad
HMSG Looking to break out
IWNN Nice Bottom Play
MMAM The real deal
MMAM Volume Coming In
RSHN Forming Handle
CNES .0012 makes for a nice add imo.
"BKMP getting bidders"
yeah .. and I'm one of them. lol. got three open orders for this one.
JAMS nice one .. doesn't look like 2.70 is going to be much of a problem here .. strong CMF .. my favorite indicator of late.
nice ... I like to limp in on the handles and load up on the breakout. seems to work for me.
Morning Hunchers... eye and ONEV .. and many others of course.
One Voice Teams-Up with Industry Leader to Bring the Digital Home Experience to Resellers Worldwide
Tuesday , February 28, 2006 15:40 ET
SAN DIEGO, Feb 28, 2006 (BUSINESS WIRE) -- One Voice Technologies, Inc. (OTCBB:ONEV), developer of 4th Generation voice solutions for the Telecom and Interactive Multimedia markets, today announced it has teamed up with an industry leader to launch an online Digital Home training program to resellers worldwide. For more information, click on http://www.onev.com/etraining
welcome to love handles albundy .. al bundy makes me laugh... is there a peg on this board? lol. Love WWAT!
LFWK Last one for the night .. chart looks beautiful .. the high stochastics are a little concerning .. but I'm not too worried. Ride the bolli baby!
ONSC One for the Flight School
This one just broke the 50dma today.
BKMP Sweet Chart
I'm sure I don't have to tell the folks here that this looks good- but this looks good. Really good.
RSI now above 50 (awesome), ADX has crossed over to positive, the big volume is there, and we closed above the middle bolli. Also, strong close above the 9dma (it's been a while). All good things.
All we need to do now is celebrate. And add. LOL.
CNES & GNTA Fun Chart Comparison
http://www.investorshub.com/boards/read_msg.asp?message_id=9933463
CVM One for Gok
CEL-SCI Receives U.S. Patent for Use of L.E.A.P.S(TM) Technology for Autoimmune Conditions and Allergies
Tuesday , February 28, 2006 10:28 ET
VIENNA, Va., Feb 28, 2006 /PRNewswire-FirstCall via COMTEX/ -- CEL-SCI CORPORATION (Amex: CVM) has been issued a U.S. patent covering its L.E.A.P.S.(TM) peptide vaccine technology in the areas of autoimmunity and allergies. The new patent, U.S. Patent No. 6,995,237, is titled, "Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions." The L.E.A.P.S. technology has also produced the patented CEL-1000 drug which induced protection in animals against viruses and parasites and is being tested by the National Institute of Allergy and Infectious Diseases against the avian flu virus.
This new patent builds on work by CEL-SCI scientists in collaboration with scientists from the laboratory of Dr. Noel Rose at The Johns Hopkins University Department of Pathology, showing that pretreatment and early therapy of Experimental Autoimmune Myocarditis with a compound developed by CEL-SCI resulted in significant reduction in heart enlargement and disease associated histopathological changes in mice. The compound used was derived from CEL-SCI's patented L.E.A.P.S. (Ligand Epitope Antigen Presentation System) platform technology.
These findings could potentially lead to the development of a treatment for autoimmune myocarditis, a life threatening heart disease, which is characterized by an enlarged and weakened heart. Myocarditis is a precursor to dilated cardiomyopathy, a condition leading to a form of chronic heart failure (CHF) characterized by an inflamed heart. End stage CHF requires a heart transplant or death ensues. The incidence in the United States alone of dilated cardiomyopathy is about 200,000 people.
The protection against experimentally induced myocarditis was statistically significant for both pretreatment and early therapy with the L.E.A.P.S compound. The response was antigen-specific and was associated with an increase in IL-13 in both the sera and heart tissue and of IL-1 alpha in the sera of the protected mice. Other studies from Dr. Rose's laboratory with IL-13 knockout-mice (mice missing the IL-13 gene) demonstrated the importance of IL-13 in this animal model of Experimental Autoimmune Myocarditis.
Dr. Daniel H. Zimmerman, Senior Vice President Research, Cellular Immunology, at CEL-SCI said, "These studies showed that we are able to treat mice with ongoing heart disease. This may lead to treatment of autoimmune myocarditis in humans where the disease process is similar to the animal model being studied and reported here. The issuance of a U.S. patent protecting our novel work is very critical to our effort."
The most well known and common autoimmune diseases are insulin dependent diabetes mellitus, rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel and Graves Disease. A common thread among these diseases is an immune response that "perceives" the person's own body, cells and organs as foreign. This, in turn, results in relentless attacks by the person's own immune system against his/her own body, eventually leading to debilitating disease, and occasionally to death. Likewise, the rejection in transplant condition is an immunologically based reaction. In immune mediated allergic reactions the L.E.A.P.S. vaccine is intended to redirect the immune response away from the harmful response in humans to a more subdued response that is not harmful. Current therapies for these conditions generally treat the symptoms of the disease but not the underlying cause of the disease as is done with the L.E.A.P.S. vaccine.
L.E.A.P.S. is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. L.E.A.P.S. compounds ("constructs") consist of a peptide epitope associated with a disease-causing agent linked to a T-cell binding peptide ligand (TCBL). Together they induce the immune system to mount either a cellular (e.g., T-cell), humoral (antibody) or a mixed immune response as a means to treat, control or prevent disease. Therefore, L.E.A.P.S. is thought to be a delivery vehicle that directs or controls the immune response to the desired outcome. This ability to preferentially direct the immune system is a major breakthrough. Any diseases for which antigenic epitope sequences have been identified, such as infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, are potential candidates for this technology. More information on L.E.A.P.S. is available at http://www.cel-sci.com.
The myocarditis work was supported in part by grants HL071352-01A1, HL67290, HL70729, AI51835 and HL077611 from National Heart, Lung and Blood Institute (NHLBI) and National Institute of Allergy and Infectious Diseases, Institutes of the National Institutes of Health (NIH).
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter Phase III clinical trials with advanced primary head and neck cancer patients. Other products, in the pre-clinical stage and funded with U.S. government support, have induced protection against a number of diseases in animal tests and are being tested against diseases associated with bio- defense and avian flu.
SOURCE CEL-SCI Corporation
Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460; or Investor Relations:
Michael Lucci, Jr. of the Lucci Financial Group, LLC, +1-248-723-3330, for CEL-SCI
Corporation
http://www.prnewswire.com
How do you like LFWK here?
All beauties fb, thanks for posting them ... especially liking ADVC and CNES.
CNES & GNTA Fun Comparison
check out Bottom Players board ..
http://www.investorshub.com/boards/board.asp?board_id=4929
agreed.